Clinical efficacy and antimicrobial pharmacodynamics
- 1 January 2000
- journal article
- review article
- Published by Mark Allen Group in Hospital Medicine
- Vol. 61 (1), 24-30
- https://doi.org/10.12968/hosp.2000.61.1.1268
Abstract
Changes in the susceptibility of bacterial pathogens and the availability of new antimicrobial drugs mean that physicians need to understand the underlying pharmacodynamics of each antimicrobial therapy. Antimicrobial pharmacodynamics determine clinical efficacy and should therefore be carefully considered when selecting appropriate antibiotic agents in the therapeutic setting.Keywords
This publication has 38 references indexed in Scilit:
- A Guide to the Treatment of Lower Respiratory Tract InfectionsDrugs, 1995
- Chronic obstructive pulmonary disease in lifelong nonsmokers: results from NHANES.American Journal of Public Health, 1995
- The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to OutcomeClinical Pharmacokinetics, 1995
- The Role of New Quinolones in the Treatment of Respiratory Tract InfectionsDrugs, 1995
- Continuous infusion of beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1992
- Antimicrobial Resistance in Streptococcus pneumoniae: An OverviewClinical Infectious Diseases, 1992
- Reports of the european study group on antibiotic breakpointsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Community-Acquired Pneumonia Requiring Hospitalization: 5-Year Prospective StudyClinical Infectious Diseases, 1989
- Quinolones in the Treatment of Lower Respiratory Tract InfectionsClinical Infectious Diseases, 1989